Calypso Biotech’s vision is to give new hope to patients suffering from severe gastro-intestinal diseases. Founded by Alain Vicari and Yolande Chvatchko in 2013, Calypso Biotech is backed by investors that include Eclosion SA, Gilde Healthcare, INKEF Capital, Johnson & Johnson Innovation, and M Ventures. Calypso Biotech is headquartered in Plan-les-ouates.